Cheaper copies of complex medicines, by the dozen: Fresenius lines up 37 biosimilars

Modern biologic medicines — antibodies and other living-cell drugs — are among the most effective and most expensive treatments in the world. Biosimilars are their close, cheaper copies. Germany's Fresenius has signed a development agreement giving it exclusive access to up to 37 biosimilar candidates over the next decade, aimed at medicines with more than €370 billion (about $414 billion) in current sales, potentially growing its portfolio from 29 molecules to as many as 66 across 13 treatment areas. Each biosimilar that reaches patients puts price pressure on a drug that today many health systems struggle to afford.

SDG 3 · Good health and well-being — Mechanism: market force